Starling Oncology (STLNW) Cash from Operations (2020 - 2026)

Starling Oncology (STLNW) has reported Cash from Operations for 7 consecutive years, with $11.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations rose 217.04% year-over-year to $11.9 million; the trailing twelve-month figure through Jun 2026 stood at $328000.0 (up 103.16% YoY), and the FY2025 full-year result was -$24.6 million, up 7.35% from the prior year.
• Cash from Operations climbed to $11.9 million in Q2 2026 per STLNW's latest filing, from -$2.2 million in the prior quarter.
• Across five years, Cash from Operations topped out at $11.9 million in Q2 2026 and bottomed at -$20.4 million in Q3 2022.
• Historically, Cash from Operations has averaged -$7.8 million across 5 years, with a median of -$9.4 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Cash from Operations sank 3759.7% in 2022, then surged 217.04% in 2026.
• Over 5 years, Cash from Operations stood at -$14.0 million in 2022, then soared by 72.19% to -$3.9 million in 2023, then surged by 202.75% to $4.0 million in 2024, then decreased by 19.18% to $3.2 million in 2025, then soared by 269.32% to $11.9 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered $11.9 million, -$2.2 million, and $3.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.